The Russian Ministry of Health announced that the first batch of “Sputnik-V” vaccine had been entered into public circulation, indicating that it had “undergone the necessary tests”, and that “it is expected that the first batches of the vaccine will be supplied to Russian regions in the near future.” .
For its part, Biontech announced that the pharmaceutical cooperation with Pfizer is able to make the vaccine ready for regulatory approval by mid-October.
The two companies indicated that they plan to provide 100 million doses of the BNT162 vaccine by the end of the year, and up to 1.3 billion doses in 2021.
In turn, Britain revealed that the process of manufacturing 30 million doses of the Oxford University vaccine is already underway, sufficient to vaccinate half of the population, adding that it hopes to launch the vaccine before the end of this year, but the vaccine will likely be launched in the first months of 2021, according to the Daily Mail.
In addition, the French company Sanofi reported that the price of its vaccine, which it is cooperating to develop with Glasgow Smith Klein, will be about 10 euros, or the equivalent of only 11 dollars, adding: The price may even be less than the price specified in advance.